SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of June 2023
Commission File Number 001-41231
TC BIOPHARM (HOLDINGS) PLC
(Translation of registrant’s name into English)
Maxim 1, 2 Parklands Way
Holytown, Motherwell, ML1 4WR
Scotland, United Kingdom
+44 (0) 141 433 7557
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
|☒ Form 20-F||☐ Form 40-F|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ ☐
Results of Annual General Meeting
On June 29, 2023, TC BioPharm (Holdings) plc (“TC BioPharm” or the “Company”) held its 2023 Annual General Meeting (the “Annual General Meeting”), and all resolutions were passed as proposed. At the Annual General Meeting, all the resolutions set out in the Notice of Annual General Meeting sent to shareholders on June 7, 2023 were duly proposed and passed on a poll.
The matters presented for a vote and the related results are as follows:
|Ordinary Resolutions||Votes For|
Resolution 1: Report and accounts
To receive the Company’s annual report and audited financial statements for the year ended 31 December 2022.
Resolution 2: Directors’ remuneration report
To receive and approve the Directors’ Remuneration Report for the year ended 31 December 2022.
Resolution 3: Directors’ remuneration policy
To receive and approve the Directors’ Remuneration Policy.
Resolution 4: Appointment of auditor
To appoint Ecovis Wingrave Yeats LLP as auditor of the Company (“Ecovis”), to hold office from the conclusion of this meeting until the conclusion of the next annual general meeting of the Company at which the Company’s financial statements are laid before the Company.
Resolution 5: Remuneration of auditor
To authorise the Audit Committee to determine the remuneration of the Auditor.
The full text of each resolution passed at the Annual General Meeting is set out in the Notice of Annual General Meeting sent to shareholders on June 7, 2023 and furnished as an exhibit to a Form 6-K filed with the U.S. Securities and Exchange Commission on June 7, 2023.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|TC BIOPHARM (HOLDINGS) PLC|
|Date: June 29, 2023||By:||/s/ Martin Thorp|
|Chief Financial Officer|